Former Acclarent Execs Convicted Of Misdemeanors In Off-Label Case
Executive Summary
Two former executives from J&J's Acclarent division were found not guilty of felony charges but convicted on misdemeanor counts. Prior to being acquired by J&J, Acclarent allegedly marketed its Relieva Stratus sinus dilation device as a steroid-delivery system, even though the FDA had cleared the device only to deliver saline.
You may also be interested in...
Court Upholds Acclarent Off-Label Marketing Convictions
The judge agreed that off-label marketing cases pose some challenges, but said the evidence against the former Acclarent execs was strong.
Acclarent Execs Move To Appeal Off-Label Conviction
Attorneys for former Acclarent executives William Facteau and Patrick Fabian have filed a request that their convictions on off-label marketing charges either be set aside or that they be granted a new trial, citing other recent off-label trials and misconduct by the government.
Acclarent Pays $18m To Settle False-Claims Allegations
The one-time payment will put to rest government claims that Acclarent marketed its Relieva Stratus device for off-label use. Two former Acclarent execs were found guilty of misdemeanors last week in a related case.